株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

組換えDNA技術市場の分析・予測:医薬品・ワクチン・遺伝子組み換え作物・特殊化学品 (スペシャルティケミカル)

Recombinant DNA Technology Market Analysis By Product (Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals), By Component, By Application, By End-use, And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 557235
出版日 ページ情報 英文 210 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
組換えDNA技術市場の分析・予測:医薬品・ワクチン・遺伝子組み換え作物・特殊化学品 (スペシャルティケミカル) Recombinant DNA Technology Market Analysis By Product (Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals), By Component, By Application, By End-use, And Segment Forecasts, 2014 - 2025
出版日: 2017年08月18日 ページ情報: 英文 210 Pages
概要

当レポートでは、世界の組換えDNA技術の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、臨床試験の動向、製品・コンポーネント・用途・エンドユーズ・地域別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場の可変因子・動向・展望

  • 市場区分・市場の範囲
    • 成長推進因子の分析
    • 成長阻害因子の分析
  • 普及率・成長の見通しマッピング
  • SWOT分析
  • ポーターの分析
  • 遺伝子治療の臨床試験実績
  • 進行中の臨床試験
  • バイオテク作物の分布:国別

第4章 市場推計・動向分析:製品別

  • 動向分析
  • 医療
    • 治療薬
    • ヒトタンパク質
    • ワクチン
  • 非医療
    • バイオテク作物
    • 特殊化学品 (スペシャルティケミカル)
    • その他

第5章 市場推計・動向分析:コンポーネント別

  • 動向分析
  • 発現系
    • 哺乳類
    • 細菌
    • 酵母
    • バキュロウィルス/昆虫
    • その他
  • クローニングベクター

第6章 市場推計・動向分析:用途別

  • 動向分析
  • 食品・農業
  • 健康・疾患
    • 人間
    • 動物
  • 環境
  • その他

第7章 市場推計・動向分析:エンドユーズ別

  • 動向分析
  • バイオテクノロジー&医薬品企業
  • 学術&政府系研究機関
  • その他

第8章 市場推計・動向分析:地域別

  • 市場シェア実績&予測
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
  • アジア太平洋
    • 中国
    • 日本
  • ラテンアメリカ
    • ブラジル
  • 中東・アフリカ
    • 南アフリカ

第9章 競合環境

  • 戦略的枠組み
  • 市場参入のカテゴリー
  • 企業プロファイル
    • Monsanto Company
    • F. Hoffmann-La Roche Ltd
    • Biogen
    • Amgen Inc
    • Novartis AG
    • Eli Lilly and Company
    • GenScript
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Sanofi
    • Merck KGaA
    • Profacgen
    • Biocon
    • GlaxoSmithKline plc.
    • Cibus
    • Horizon Discovery Group plc
    • New England Biolabs
目次
Product Code: GVR-1-68038-872-5

The global recombinant DNA technology market is expected to reach USD 844.6 billion by 2025, according to a new report by Grand View Research, Inc. Success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA (rDNA) technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.

Widespread successful application of this technique in veterinary product development, genetically modified crop development, bio pesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period.

Use of Genetically Modified (GM) products, such as GM animals, developed using rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess the GM products safety in context to its impact on human health and environment.

In addition, there is rising need to improve the recombinant proteins' production capacity by several folds, owing to increase in demand for effective therapeutics for disease treatment. The aforementioned fact pronounces the technological advances in this sector thus driving growth.

As per Monsanto and other proponents of GM crops, genetic engineering is one of the fastest and widely adopted agricultural innovations over the past few years. This, in turn, is expected bolster the adoption of rDNA technology for non-traditional applications.

Further key findings from the report suggest:

  • Medical rDNA products dominated the share in 2016 in terms of revenue generation
  • This can be attributed to the commercial success of insulin which has prompted firms for further development of recombinant drugs
  • Owing to efficient transient and stable expression capabilities, mammalian expression system captured the largest share
  • This share is also supported by the improvements in media for high yield using mammalian expression system
  • Health & disease accounted with the largest share in revenue
  • Gene therapy, antibodies production, drug metabolism investigation, recombinant therapeutic & vaccine development are recognized as major applications of this technology in human healthcare management
  • Various end-use segments served by this market encompass pharmaceutical & biotech entities, academic & research institutes, and other industrial entities
  • End-use wise, pharmaceutical and biotechnology firms are estimated to be the largest segment owing to the presence of substantial number of biopharma entities that have adopted rDNA products
  • North America held the largest share owing to the presence of effective regulations pertaining to the approval of recombinant therapeutics as well as GM products
  • Asia Pacific is expected to emerge as the fastest growing regional market
  • Conducting clinical trials in Asian countries such as India is relatively less expensive compared to western countries. This has resulted into migration of several global biopharmaceutical developers towards this region
  • Biogen; Amgen Inc., Eli Lilly and Company, Monsanto Company, Novartis AG, and F. Hoffmann-La Roche Ltd are some of the major companies operating in this space

Table of Content

Chapter 1 Research Methodology

  • 1.1 Information Procurement
    • 1.1.1 Purchased Database
    • 1.1.2 GVR's Internal Database
  • 1.2 Data Analysis
  • 1.3 Market Formulation & Validation
  • 1.4 Approaches for Market Estimation
    • 1.4.1 Approach 1: Commodity Flow & Bottom Up Approach
    • 1.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Recombinant DNA Technology Market Variables, Trends & Scope

  • 3.1 Market Segmentation &Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Huge success of recombinant insulin
      • 3.1.1.2 Expansion of biopharmaceutical industry
      • 3.1.1.3 Technological advancements in genomics:
      • 3.1.1.3.1 Gene editing tools
      • 3.1.1.3.2 Expression system
      • 3.1.1.4 Increasing demand as well as application of recombinant/ genetically modified products
      • 3.1.1.4.1 Human & animal healthcare
      • 3.1.1.4.2 Food & agriculture
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
      • 3.1.2.2 Risks pertaining to the usage of genetically modified food
  • 3.2 Penetration &Growth Prospect Mapping For Application, 2016
  • 3.3 Recombinant DNA Technology-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.4 Industry Analysis - Porter's
  • 3.5 Clinical Trials In Gene Therapy Around The World, 2016
  • 3.6 List Of Ongoing Clinical Trials In Gene Therapy
  • 3.7 Distribution of Biotech Crops, By Country

Chapter 4 Recombinant DNA Technology Market: Product Estimates & Trend Analysis

  • 4.1 Global Recombinant DNA Technology Market: Product Movement Analysis
  • 4.2 Medical
    • 4.2.1 Global medical product market, 2014 - 2025 (USD Billion)
    • 4.2.2 Therapeutic agent
      • 4.2.2.1 Global therapeutic agent market, 2014 - 2025 (USD Billion)
    • 4.2.3 Human protein
      • 4.2.3.1 Global human protein market, 2014 - 2025 (USD Billion)
    • 4.2.4 Vaccine
      • 4.2.4.1 Global vaccine market, 2014 - 2025 (USD Billion)
  • 4.3 Non-medical
    • 4.3.1 Global non-medical product market, 2014 - 2025 (USD Billion)
    • 4.3.2 Biotech crops
      • 4.3.2.1 Global biotech crops market, 2014 - 2025 (USD Billion)
    • 4.3.3 Specialty chemical
      • 4.3.3.1 Global Specialty chemical market, 2014 - 2025 (USD Billion)
    • 4.3.4 Others
      • 4.3.4.1 Global other non-medical product market, 2014 - 2025 (USD Billion)

Chapter 5 Recombinant DNA Technology: Component Estimates & Trend Analysis

  • 5.1 Global Recombinant DNA Technology Market: Component Movement Analysis
  • 5.2 Expression System
    • 5.2.1 Global expression system market, 2014 - 2025 (USD Billion)
    • 5.2.2 Mammalian
      • 5.2.2.1 Global mammalian market, 2014 - 2025 (USD Billion)
    • 5.2.3 Bacteria
      • 5.2.3.1 Global bacteria market, 2014 - 2025 (USD Billion)
    • 5.2.4 Yeast
      • 5.2.4.1 Global yeast market, 2014 - 2025 (USD Billion)
    • 5.2.5 Baculovirus/insect
      • 5.2.5.1 Global baculovirus/insect market, 2014 - 2025 (USD Billion)
    • 5.2.6 Others
      • 5.2.6.1 Global others market, 2014 - 2025 (USD Billion)
  • 5.3 Cloning Vector
    • 5.3.1 Global cloning vector market, 2014 - 2025 (USD Billion)

Chapter 6 Recombinant DNA Technology: Application Estimates & Trend Analysis

  • 6.1 Global Recombinant DNA Technology Market: Application Movement Analysis
  • 6.2 Food & Agriculture
    • 6.2.1 Global food & agriculture market, 2014 - 2025 (USD Billion)
  • 6.3 Health & Disease
    • 6.3.1 Global health & disease market, 2014 - 2025 (USD Billion)
    • 6.3.2 Human
      • 6.3.2.1 Global human market, 2014 - 2025 (USD Billion)
    • 6.3.3 Animal
      • 6.3.3.1 Global animal market, 2014 - 2025 (USD Billion)
  • 6.4 Environment
    • 6.4.1 Global environment market, 2014 - 2025 (USD Billion)
  • 6.5 Others
    • 6.5.1 Global other applications market, 2014 - 2025 (USD Billion)

Chapter 7 Recombinant DNA Technology: End-use Estimates & Trend Analysis

  • 7.1 Global Recombinant DNA Technology Market: End-use Movement Analysis
  • 7.2 Biotechnology and Pharmaceutical Companies
    • 7.2.1 Global biotechnology and pharmaceutical companies market, 2014 - 2025 (USD Billion)
  • 7.3 Academic & Government Research Institutes
    • 7.3.1 Global academic & government research institutes market, 2014 - 2025 (USD Billion)
  • 7.4 Others
    • 7.4.1 Global other end-use market, 2014 - 2025 (USD Billion)

Chapter 8 Recombinant DNA Technology: Regional Estimates & Trend Analysis, by Product, Component, Application, & End-use

  • 8.1 Recombinant DNA Technology Market Share By Region, 2016 & 2025
  • 8.2 North America
    • 8.2.1 North America recombinant DNA Technology market, 2014 - 2025 (USD Billion)
    • 8.2.2 U.S.
      • 8.2.2.1 U.S. recombinant DNA Technology market, 2014 - 2025 (USD Billion)
    • 8.2.3 Canada
      • 8.2.3.1 Canada recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • 8.3 Europe
    • 8.3.1 Europe recombinant DNA technology market, 2014 - 2025 (USD Billion)
    • 8.3.2 Germany
      • 8.3.2.1 Germany recombinant DNA technology market, 2014 - 2025 (USD Billion)
    • 8.3.3 UK
      • 8.3.3.1 UK recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific recombinant DNA technology market, 2014 - 2025 (USD Billion)
    • 8.4.2 China
      • 8.4.2.1 China recombinant DNA technology market, 2014 - 2025 (USD Billion)
    • 8.4.3 Japan
      • 8.4.3.1 Japan recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • 8.5 Latin America
    • 8.5.1 Latin America recombinant DNA technology market, 2014 - 2025 (USD Billion)
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • 8.6 Middle East & Africa (MEA)
    • 8.6.1 MEA recombinant DNA technology market, 2014 - 2025 (USD Billion)
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa recombinant DNA technology market, 2014 - 2025 (USD Billion)

Chapter 9 Competitive Landscape

  • 9.1 Strategy Framework
  • 9.2 Market Participation Categorization
  • 9.3 Company Profiles
    • 9.3.1 Monsanto Company
      • 9.3.1.1 Company overview
      • 9.3.1.2 Financial performance
      • 9.3.1.3 Product benchmarking
      • 9.3.1.4 Strategic initiatives
    • 9.3.2 F. Hoffmann-La Roche Ltd
      • 9.3.2.1 Company overview
      • 9.3.2.1.1 Genentech, Inc
      • 9.3.2.2 Financial performance
      • 9.3.2.3 Product benchmarking
    • 9.3.3 Biogen
      • 9.3.3.1 Company overview
      • 9.3.3.2 Financial performance
      • 9.3.3.3 Product benchmarking
      • 9.3.3.4 Strategic initiatives
    • 9.3.4 Amgen Inc
      • 9.3.4.1 Company overview
      • 9.3.4.2 Financial performance
      • 9.3.4.3 Product benchmarking
    • 9.3.5 Novartis AG
      • 9.3.5.1 Company overview
      • 9.3.5.1.1 Chiron Corporation
      • 9.3.5.2 Financial performance
      • 9.3.5.3 Product benchmarking
      • 9.3.5.4 Strategic initiatives
    • 9.3.6 Eli Lilly and Company
      • 9.3.6.1 Company overview
      • 9.3.6.2 Financial performance
      • 9.3.6.3 Product benchmarking
      • 9.3.6.4 Strategic initiatives
    • 9.3.7 GenScript
      • 9.3.7.1 Company overview
      • 9.3.7.2 Financial performance
      • 9.3.7.3 Product benchmarking
      • 9.3.7.4 Strategic initiatives
    • 9.3.8 Pfizer Inc.
      • 9.3.8.1 Company overview
      • 9.3.8.1.1 Bamboo Therapeutics, Inc.
      • 9.3.8.2 Financial performance
      • 9.3.8.3 Product benchmarking
      • 9.3.8.4 Strategic initiatives
    • 9.3.9 Novo Nordisk A/S
      • 9.3.9.1 Company overview
      • 9.3.9.2 Financial performance
      • 9.3.9.3 Product benchmarking
    • 9.3.10 Sanofi
      • 9.3.10.1 Company overview
      • 9.3.10.2 Financial performance
      • 9.3.10.3 Product benchmarking
      • 9.3.10.4 Strategic initiatives
    • 9.3.11 Merck KGaA
      • 9.3.11.1 Company overview
      • 9.3.11.2 Financial performance
      • 9.3.11.3 Product benchmarking
    • 9.3.12 Profacgen
      • 9.3.12.1 Company overview
      • 9.3.12.2 Financial performance
      • 9.3.12.3 Product benchmarking
    • 9.3.13 Biocon
      • 9.3.13.1 Company overview
      • 9.3.13.1.1 Syngene
      • 9.3.13.2 Financial performance
      • 9.3.13.3 Product benchmarking
    • 9.3.14 GlaxoSmithKline plc.
      • 9.3.14.1 Company overview
      • 9.3.14.2 Financial performance
      • 9.3.14.3 Product benchmarking
      • 9.3.14.4 Strategic initiatives
    • 9.3.15 Cibus
      • 9.3.15.1 Company overview
      • 9.3.15.1.1 Nucelis
      • 9.3.15.2 Financial performance
      • 9.3.15.2.1 Financial performance
      • 9.3.15.3 Product benchmarking
      • 9.3.15.4 Strategic initiatives
    • 9.3.16 Horizon Discovery Group plc
      • 9.3.16.1 Company overview
      • 9.3.16.2 Financial performance
      • 9.3.16.3 Product benchmarking
      • 9.3.16.4 Strategic initiatives
    • 9.3.17 New England Biolabs
      • 9.3.17.1 Company overview
      • 9.3.17.2 Financial performance
      • 9.3.17.3 Product benchmarking
      • 9.3.17.4 Strategic initiatives

List of Tables

  • TABLE 1 Approved recombinant insulins for human use
  • TABLE 2 Some commercially available drug produced by recombinant DNA technology
  • TABLE 3 Plant-based human vaccines in clinical trials, 2015
  • TABLE 4 Plant-based vaccines for veterinary use
  • TABLE 5 Most widely used cell factories used for biopharmaceutical production between 2010 - 2014
  • TABLE 6 Various gene therapy approaches employed for various disease treatment
  • TABLE 7 North America recombinant DNA Technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 8 North America medical recombinant DNA Technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 9 North America non-medical recombinant DNA Technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 10 North America recombinant DNA Technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 11 North America expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 12 North America recombinant DNA Technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 13 North America health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 14 North America recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 15 U.S. recombinant DNA Technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 16 U.S. medical recombinant DNA Technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 17 U.S. non-medical recombinant DNA Technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 18 U.S. recombinant DNA Technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 19 U.S. expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 20 U.S. recombinant DNA Technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 21 U.S. health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 22 U.S. recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 23 Canada recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 24 Canada medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 25 Canada non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 26 Canada recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 27 Canada expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 28 Canada recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 29 Canada health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 30 Canada recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 31 Europe recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 32 Europe medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 33 Europe non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 34 Europe recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 35 Europe expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 36 Europe recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 37 Europe health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 38 Europe recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 39 Germany recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 40 Germany medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 41 Germany non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 42 Germany recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 43 Germany expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 44 Germany recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 45 Germany health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 46 Germany recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 47 UK recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 48 UK medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 49 UK non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 50 UK recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 51 UK expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 52 UK recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 53 UK health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 54 UK recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 55 Asia Pacific recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 56 Asia Pacific medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 57 Asia Pacific non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 58 Asia Pacific recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 59 Asia Pacific expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 60 Asia Pacific recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 61 Asia Pacific health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 62 Asia Pacific recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 63 China recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 64 China medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 65 China non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 66 China recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 67 China expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 68 China recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 69 China health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 70 China recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 71 Japan recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 72 Japan medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 73 Japan non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 74 Japan recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 75 Japan expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 76 Japan recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 77 Japan health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 78 Japan recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 79 Latin America recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 80 Latin America medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 81 Latin America non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 82 Latin America recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 83 Latin America expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 84 Latin America recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 85 Latin America health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 86 Latin America recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 87 Brazil recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 88 Brazil medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 89 Brazil non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 90 Brazil recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 91 Brazil expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 92 Brazil recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 93 Brazil health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 94 Brazil recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 95 MEA recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 96 MEA medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 97 MEA non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 98 MEA recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 99 MEA expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 100 MEA recombinant DNA technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 101 MEA health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 102 MEA recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)
  • TABLE 103 South Africa recombinant DNA technology market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 104 South Africa medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 105 South Africa non-medical recombinant DNA technology product market estimates & forecasts, by product, 2014 - 2025 (USD Billion)
  • TABLE 106 South Africa recombinant DNA technology market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 107 South Africa expression vector market estimates & forecasts, by component, 2014 - 2025 (USD Billion)
  • TABLE 108 South Africa recombinant DNA Technology market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 109 South Africa health & disease market estimates & forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 110 South Africa recombinant DNA technology market estimates & forecasts, by end-use, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Various biopharmaceutical categories offered by company
  • FIG. 12 Comparison of R&D biotech pipeline expansion for recombinant products
  • FIG. 13 Cumulative success rate comparison of biologics with small molecules over time
  • FIG. 14 Number of biologics investigational new drugs, 2005-2015
  • FIG. 15 Global area of biotech crops, 1996 to 2016 (hectares; millions)
  • FIG. 16 Global impact of biotech crop adoption in 2014
  • FIG. 17 Market restraint relevance analysis (Current & future impact)
  • FIG. 18 Various ethical questions raised by gene therapy
  • FIG. 19 Side effects of GM products
  • FIG. 20 Penetration & growth prospect mapping for application, 2016
  • FIG. 21 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 22 Porter's Five Forces Analysis
  • FIG. 23 Clinical Trials In Gene Therapy Around The World, 2016
  • FIG. 24 Global recombinant DNA technology market: Product outlook key takeaways
  • FIG. 25 Global Recombinant DNA Technology market: Source movement analysis
  • FIG. 26 Global medical product market, 2014 - 2025 (USD Billion)
  • FIG. 27 Global therapeutic agent market, 2014-2025 (USD Billion)
  • FIG. 28 Global human protein market, 2014-2025 (USD Billion)
  • FIG. 29 Global vaccine market, 2014-2025 (USD Billion)
  • FIG. 30 Global non-medical product market, 2014 - 2025 (USD Billion)
  • FIG. 31 Global recombinant DNA technology market: Component outlook key takeaways
  • FIG. 32 Global Recombinant DNA Technology market: Component movement analysis
  • FIG. 33 Global expression system market, 2014 - 2025 (USD Billion)
  • FIG. 34 Global mammalian market, 2014 - 2025 (USD Billion)
  • FIG. 35 Global bacteria market, 2014 - 2025 (USD Billion)
  • FIG. 36 Global yeast market, 2014 - 2025 (USD Billion)
  • FIG. 37 Global baculovirus/insect market, 2014 - 2025 (USD Billion)
  • FIG. 38 Global others market, 2014 - 2025 (USD Billion)
  • FIG. 39 Global cloning vector market, 2014 - 2025 (USD Billion)
  • FIG. 40 Global recombinant DNA technology market: Application outlook key takeaways
  • FIG. 41 Global Recombinant DNA Technology market: Application movement analysis
  • FIG. 42 Global food & agriculture market, 2014 - 2025 (USD Billion)
  • FIG. 43 Global health & disease market, 2014 - 2025 (USD Billion)
  • FIG. 44 Global human market, 2014 - 2025 (USD Billion)
  • FIG. 45 Global animal market, 2014 - 2025 (USD Billion)
  • FIG. 46 Global environment market, 2014 - 2025 (USD Billion)
  • FIG. 47 Global other applications market, 2014 - 2025 (USD Billion)
  • FIG. 48 Global recombinant DNA technology market: End-use outlook key takeaways
  • FIG. 49 Global Recombinant DNA Technology market: End-use movement analysis
  • FIG. 50 Global biotechnology and pharmaceutical companies market, 2014 - 2025 (USD Billion)
  • FIG. 51 Global academic & government research institutes market, 2014 - 2025 (USD Billion)
  • FIG. 52 Global other end-use market, 2014 - 2025 (USD Billion)
  • FIG. 53 Regional market place: Key takeaway
  • FIG. 54 Recombinant DNA Technology regional outlook, 2016 & 2025
  • FIG. 55 North America recombinant DNA Technology market, 2014 - 2025 (USD Billion)
  • FIG. 56 U.S. recombinant DNA Technology market, 2014 - 2025 (USD Billion)
  • FIG. 57 Canada recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 58 Europe recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 59 Germany recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 60 UK recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 61 Asia Pacific recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 62 China recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 63 Japan recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 64 Latin America recombinant DNA technology market, 2014-2025 (USD Billion)
  • FIG. 65 Brazil recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 66 Middle East & Africa recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 67 South Africa recombinant DNA technology market, 2014 - 2025 (USD Billion)
  • FIG. 68 Strategy framework
  • FIG. 69 Participant categorization
Back to Top